Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study)

BACKGROUND: The global transition to use of dolutegravir (DTG) in WHO-preferred regimens for HIV treatment is limited by lack of knowledge on use in pregnancy. Here we assessed the relationship between drug concentrations (pharmacokinetics, PK), including in breastmilk, and impact on viral suppressi...

Descripción completa

Detalles Bibliográficos
Autores principales: Waitt, Catriona, Orrell, Catherine, Walimbwa, Stephen, Singh, Yashna, Kintu, Kenneth, Simmons, Bryony, Kaboggoza, Julian, Sihlangu, Mary, Coombs, Julie-Anne, Malaba, Thoko, Byamugisha, Josaphat, Amara, Alieu, Gini, Joshua, Else, Laura, Heiburg, Christie, Hodel, Eva Maria, Reynolds, Helen, Mehta, Ushma, Byakika-Kibwika, Pauline, Hill, Andrew, Myer, Landon, Lamorde, Mohammed, Khoo, Saye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6754125/
https://www.ncbi.nlm.nih.gov/pubmed/31539371
http://dx.doi.org/10.1371/journal.pmed.1002895

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6754125/
https://www.ncbi.nlm.nih.gov/pubmed/31539371
http://dx.doi.org/10.1371/journal.pmed.1002895

Ejemplares similares